戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ase to characterize the genomic landscape of gliosarcoma.
2 estricted to the mesenchymal tumor area of a gliosarcoma.
3 e to treat glioblastoma multiforme (GBM) and gliosarcoma.
4 e days after intracranial implantation of 9L gliosarcoma.
5 eukocyte populations infiltrating the rat 9L gliosarcoma.
6 oplastic cells additionally expressed FAP in gliosarcoma.
7 e sarcoma alone, and 9 were more distinct to gliosarcoma.
8 1 patients who were enrolled, 13 of them had gliosarcoma.
9 n in glial and mesenchymal tumor areas of 13 gliosarcomas.
10  of 125IUdR in rats bearing intracerebral 9L gliosarcomas.
11 ions derived from normal animals and from 9L gliosarcomas.
12 described in glioblastomas and especially in gliosarcomas.
13 n neoplasms (4 of 12, 33%; 1 glioblastoma, 1 gliosarcoma, 1 astrocytoma, 1 unspecified type) and schw
14                              In rats with 9L gliosarcoma, [(18)F]9 and [(18)F]28 provided high tumor
15 2.1% +/- 0.3 (standard error of mean) for 9L gliosarcoma, 3.1% +/- 0.4 for DU4475 mammary adenocarcin
16                    Of the 19 common genes in gliosarcoma, 6 were also common in both GBM and soft tis
17                                          Rat gliosarcoma 9L cells stably expressing ETR (ETR+) were u
18 opoietic lineage (bladder carcinoma BC47 and gliosarcoma 9L).
19 mes extravasate in tumors such as the rat 9L gliosarcoma and accumulate in perivascular areas.
20  the clinical relevance of FAP expression in gliosarcoma and glioblastoma and how it correlates with
21  barrier in both the 9L (6-fold improvement) gliosarcoma and invasive F98 (28-fold improvement) gliom
22 om p-boronophenylalanine (BPA) in the 9L rat gliosarcoma and the F98 rat glioma brain tumor models.
23 ate its therapeutic outcome on the rodent 9L gliosarcoma and the human U87 glioblastoma models.
24           We analyzed genomic alterations in gliosarcomas and compared them to GBM (n = 1,449) and so
25 cal resection, and histology (glioblastoma v gliosarcoma) and then randomly assigned to arm A (BCNU p
26  within glioma cells, collagen deposition in gliosarcoma, and irregularity and disruption of myelinat
27 patients with glioblastoma, three (17%) with gliosarcoma, and one (6%) with anaplastic ependymoma.
28 and mesenchymal tumor areas, suggesting that gliosarcomas are genetically monoclonal, and mesenchymal
29 toma and a particularly strong expression in gliosarcoma attributed to traits of predominant mesenchy
30 increased tumor capillary permeability in 9L gliosarcoma-bearing rats with no significant increase in
31    Despite their unique histologic features, gliosarcomas belong to the group of glioblastomas and ar
32 phenylalanine-fructose (BPA-F) in the rat 9L gliosarcoma brain tumor model.
33          Recently, we showed that the rat 9L gliosarcoma cell line, which does not express BEHAB/brev
34 immunization of rats with IL-4 transduced 9L gliosarcoma cells (9L-IL-4) induced a potent antitumor i
35                                       The 9L gliosarcoma cells assays showed that 4b is mainly a subs
36    The kinetics of viral infection of rat 9L gliosarcoma cells by the replication-conditional HSV-1 v
37         Amino acid transport assays using 9L gliosarcoma cells demonstrated that both compounds are s
38   We have found that vaccination with rat 9L gliosarcoma cells expressing interleukin 4 (9LmIL4) indu
39 es for amino acid transport and enter 9L rat gliosarcoma cells in vitro at least in part by system A
40 es the cytotoxic events induced by CPA in 9L gliosarcoma cells retrovirally transduced with CYP2B6, o
41                                       Rat 9L gliosarcoma cells stably expressing either basal or elev
42                  Here, we transformed rat 9L gliosarcoma cells to express cel-miR-67, a miRNA that la
43                                           9L gliosarcoma cells transduced with the CPA-activating enz
44                                           9L gliosarcoma cells were implanted in both hemispheres in
45                                       The 9L gliosarcoma cells were implanted in the brain of eight r
46 inant retroviruses were used to transduce 9L gliosarcoma cells with the genes encoding P450 2B6 and N
47          Three days after implantation of 9L gliosarcoma cells, 125IUdR was administered intrathecall
48 transport assays performed in vitro using 9L gliosarcoma cells, both [18F]16 and [18F]17 were substra
49     In rats implanted intracranially with 9L gliosarcoma cells, the retention of radioactivity in tum
50  a concentration of 10 muM against rat 9L-SF gliosarcoma cells.
51 ated the antitumor effect of ErPC3 in 9L rat gliosarcoma cells.
52 of glioblastoma, anaplastic astrocytoma, and gliosarcoma cells.
53  cytotoxicity in a population of infected 9L gliosarcoma cells.
54 ecal (i.t.) implantation of 5 x 10(5) 9L rat gliosarcoma cells.
55 A- or IFA-metabolizing human CYP genes to 9L gliosarcoma cells: 2B6, 2C8, 2C9, 2C18 (Met385 and Thr38
56  MCF7 (breast), DU145 (prostate), and SF539 (gliosarcoma) cells were exposed to a total radiation dos
57     Active Cy annexin was used to image a 9L gliosarcoma, constitutively expressing green fluorescent
58                                              Gliosarcoma contains molecular features that overlap GBM
59 83), anaplastic glioma (U-87MG and U-138MG), gliosarcoma (D-32GS), or normal human astrocytes demonst
60     Nineteen common genes were identified in gliosarcoma, defined as those altered in > 5% of samples
61  differing degrees of angiogenesis-9L rodent gliosarcoma, DU4475 human mammary adenocarcinoma, HT1080
62 lioblastoma multiforme, gliomatosis cerebri, gliosarcoma, ependymoma, and subependymoma, for their po
63                                     Although gliosarcomas express higher levels of FAP than do gliobl
64 6; anaplastic oligodendroglioma [AO], n = 2; gliosarcoma [GS], n = 1; and metastatic adenocarcinoma,
65                        Cell assays in rat 9L gliosarcoma, human U87 DeltaEGFR glioblastoma, and human
66 FDG) in which the uptake of each agent in 9L gliosarcoma (implanted intracerebrally in Fisher 344 rat
67 ion of 123IUdR/125IUdR into intracerebral 9L gliosarcomas in rats results in selective uptake of the
68 mas (intratumoral injection), or intrathecal gliosarcomas (intrathecal injection).
69 cer (*IUdR by intravesical injection), brain gliosarcomas (intratumoral injection), or intrathecal gl
70                                              Gliosarcoma is a rare glioblastoma variant characterized
71                                              Gliosarcoma is an aggressive brain tumor with histologic
72 esenchymal components in a small fraction of gliosarcomas may be derived from glial cells with additi
73 l fibroblasts) as well as in tumor cells (9L gliosarcoma, MCF7 adenocarcinoma, and HT-1080 fibrosarco
74 sted in vivo by treating an intracranial 9 L gliosarcoma model in F344 rats.
75 tial for this disease in a 9L rat orthotopic gliosarcoma model using a combination of noninvasive ima
76 umor mass and increased survival in a rat 9L gliosarcoma model, whereas individual monotherapies were
77                                              Gliosarcoma mutations with potential therapeutic indicat
78             Methods: Patients diagnosed with gliosarcoma or glioblastoma without sarcomatous differen
79         Sequencing data was obtained from 35 gliosarcoma patients from Genomics Evidence Neoplasia In
80       Experiments were performed with the 9L gliosarcoma rat model using a needle oxygen electrode to
81 b locally in the brain in an intracranial 9L gliosarcoma rat model.
82 nsgenic SF/HGF expression by intracranial 9L gliosarcomas reduced tumor cell sensitivity to gamma irr
83              i.p. injection of BPA in the 9L gliosarcoma resulted in a tumor-to-brain (T:Br) boron-10
84 s 3- and 6-h i.v. infusions of BPA in the 9L gliosarcoma resulted in similar high boron-10 concentrat
85           Co-implantation of NanoMesh and 9L gliosarcoma resulted in statistically significant long-t
86                                            A gliosarcoma rodent model was established to determine th
87               Like human gliomas, the rat 9L gliosarcoma secretes the immunosuppressive transforming
88  experiments with cannulated rats bearing 9L gliosarcoma showed a preferential localization of the TA
89  FAP expression is much more abundant in the gliosarcoma subgroup of glioblastomas.
90 chemistry revealed significantly more FAP in gliosarcomas than in glioblastomas without sarcomatous d
91                                    In the 9L gliosarcoma, this ratio was 2.9:1 after i.p. administrat
92 ischer rats implanted intracranially with 9L gliosarcoma tumor cells were also performed.
93 2-h i.v. infusion of BPA in rats with the 9L gliosarcoma, tumor boron-10 concentrations were 2.7 time
94 ow-derived dendritic cells (DCs) into rat 9L gliosarcoma tumors and into 9L tumors induced to undergo
95  rats and mice orthotopically implanted with gliosarcoma tumors or glioma stem-like cells, respective
96                           In rats bearing 9L gliosarcoma tumors, 4b displayed high tumor to brain rat
97              Further analyses of 64 cases of gliosarcoma using quantitative PCR showed amplification
98  eligible adults with newly diagnosed GBM or gliosarcoma were enrolled.
99           Forty-eight male rats bearing a 9L gliosarcoma were randomized in untreated and treated (so
100                             Using a model of gliosarcoma with stably green fluorescence protein-expre
101 of orthotopic glioma (SF188/V+ glioma and 9L gliosarcoma) with a model of radiation necrosis in rats,
102  not always achieved, as shown here, when 9L gliosarcoma xenografts were treated over a range of dose

 
Page Top